Radiogenomics is gaining traction beyond the Mayo Clinic, but significant regulatory hurdles remain. The complexity of deep learning algorithms complicates the approval process, as understanding their decision-making is crucial for patient safety. Optimism exists for a collaborative approach among regulatory agencies, industry, and academia to enhance patient care through these advanced technologies.
